Skip to main content

Phathom Pharmaceuticals, Inc.

PHAT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001783183

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026
$492.6M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −11 vs. previous quarter
161
13F valueReported value at the end of Q2 2026
$782.1M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$175.1M
+216.9% year over year
Net income, FY2025
-$221.2M
No comparable prior period
Free cash flow, FY2025
-$167.0M
No comparable prior period
Revenue, Q3 FY2026
$84.7M
+71.1% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $221.2M (126.3% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
9.20M
Shares sold short
Change
−580.1K
−5.9% vs. previous
Days to cover
4.83
At average daily volume

Superinvestors holding PHAT, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding PHAT at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Phathom Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 5, 2025 (view filing)Nov 32 daysBreedlove Robert CharlesPrincipal Accounting OfficerSSale−524$13.51−$7.08K−1.1%47.4K after
Sep 9, 2025 (view filing)Sep 54 daysBreedlove Robert CharlesPrincipal Accounting OfficerSSale−461$12.09−$5.57K−1.0%47.9K after
Jul 18, 2025 (view filing)Jul 162 daysBreedlove Robert CharlesPrincipal Accounting OfficerSSale−1.69K$8.36−$14.1K−3.4%48.4K after
May 23, 2025 (view filing)May 212 daysTopper James NDirectorPPurchase+3.78K$3.86+$14.6K+6.8%59.4K after
May 15, 2025 (view filing)May 13-142 daysTopper James NDirectorPPurchase+7.42K$3.30+$24.5K+15.4%55.6K after2 lots
May 13, 2025 (view filing)May 9-124 daysTopper James NDirectorPPurchase+48.2K$3.17+$152.8KNew position48.2K after3 lots
May 8, 2025 (view filing)May 6-72 daysParikh AsitDirectorPPurchase+10.0K$2.50+$25.0K+11.7%95.5K after2 lots
Apr 8, 2025 (view filing)Apr 71 dayHenderson MollyCFO and CBOSSale−3.68K$4.55−$16.7K−3.9%89.9K after
Mar 17, 2025 (view filing)Mar 134 daysParikh AsitDirectorPPurchase+10.0K$4.42+$44.2K+13.2%85.5K after
Jan 23, 2025 (view filing)Jan 212 daysHenderson MollyCFO and CBOSSale−6.58K$6.59−$43.4K−6.6%93.5K after

Top 10 13F holders, Q2 2026

See all 161 holders

The largest institutional positions in Phathom Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding PHAT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Frazier Life Sciences Management, L.P.12,466,489$135.3M2.95%00.0%Unchanged
Medicxi Ventures Management (Jersey) Ltd7,464,572$81.0M45.65%00.0%Unchanged
BlackRock, Inc.4,525,129$49.1M0.00%+463,133+11.4%Added
Invesco Ltd.4,029,731$43.7M0.00%−292,329−6.8%Reduced
Carlyle Group Inc.3,496,808$37.9M0.38%00.0%Unchanged
Millennium Management LLC3,375,834$36.6M0.02%−647,075−16.1%Reduced
Vanguard Capital Management LLC2,656,944$28.8M0.00%+73,308+2.8%Added
GW&K Investment Management, LLC2,166,838$23.5M0.18%+745,729+52.5%Added
Franklin Resources Inc1,970,828$21.4M0.00%+976,324+98.2%Added
NEA Management Company, LLC1,960,169$21.3M1.34%00.0%Unchanged

Holders of 5% or more of PHAT

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Phathom Pharmaceuticals, Inc..

Largest holders of PHAT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Frazier Life Sciences Public Fund, L.P.13D/A7.40%6.01M shares−1.20 ppfrom 8.60%May 5, 20238 filingsNov 2, 2026SEC
BlackRock, Inc.13G5.50%4.38M shares+0.90 ppfrom 4.60%Oct 21, 20244 filingsJul 29, 2026SEC